474 reports of this reaction
3.2% of all TERBINAFINE HYDROCHLORIDE reports
#2 most reported adverse reaction
RASH is the #2 most commonly reported adverse reaction for TERBINAFINE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 474 FDA adverse event reports linking TERBINAFINE HYDROCHLORIDE to RASH. This represents approximately 3.2% of all 14,851 adverse event reports for this drug.
Patients taking TERBINAFINE HYDROCHLORIDE who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among TERBINAFINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for TERBINAFINE HYDROCHLORIDE:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 474 FDA reports for TERBINAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 3.2% of all adverse event reports for TERBINAFINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience rash while taking TERBINAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.